Trials / Completed
CompletedNCT05833022
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 297 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- —
Summary
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.
Conditions
Timeline
- Start date
- 2021-07-30
- Primary completion
- 2022-04-18
- Completion
- 2022-04-18
- First posted
- 2023-04-27
- Last updated
- 2023-04-27
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05833022. Inclusion in this directory is not an endorsement.